Standigm announced today that it has launched two AI-driven drug discovery services, Expander and Hunter. Expander is a service that new and better indications for customer’s in-house compounds. By using Expander service, pharmaceutical companies are now able to achieve a quick identification of a novel clinical use for their existing drugs with low cost and effort. Hunter, another service other than Expander, discovers repositioned lead compounds tailored to customer’s interest. Hunter is based on Standigm’s state-of-the-art AI technology and searches for potential drugs, protein targets to combat the specific diseases that our customers are interested in. .
Standigm and Korea institute of science and technology (KIST) announced a research collaboration to develop a new small molecule medicine for Autism. The drug candidates chosen by Standigm’s AI drug discovery technology will validate experimentally by using KIST’s animal models.